TVA Medical, Inc., announced primary endpoint data from a prospective, multicenter clinical study evaluating the everlinQ™ endoAVF System. This novel medical technology creates an arteriovenous (AV) fistula for hemodialysis access in people with end-state kidney disease (ESKD) using an endovascular approach in vessels not traditionally used during surgery. (Read More)